ストックスクリーナーアプリを入手
127.85
0.04%
-0.05
アフターアワーズ：
127.76
-0.09
-0.07%
Blueprint Medicines Corp (BPMC) 最新ニュース
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta - Benzinga
Blueprint Medicines (BPMC): Morgan Stanley Raises Price Target | BPMC Stock News - GuruFocus
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal - TradingView
Citigroup Upgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Sanofi to acquire Blueprint Medicines for about $9.1B - Drug Store News
Blueprint Medicines (BPMC) Target Price Raised by UBS Analyst | - GuruFocus
Blueprint Medicines (BPMC) Sees Price Target Increase Amid Acquisition News | BPMC Stock News - GuruFocus
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines (BPMC) Target Price Increased Following Acqu - GuruFocus
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform - Insider Monkey
Kalkine: How Is Blueprint Medicines (NASDAQ:BPMC) Positioned Within the Nasdaq Composite Framework? - Kalkine Media
Sanofi to Buy Blueprint for $9.1 Billion Equity Value - MSN
Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion - MSN
BPMC Stock Upgraded: Citigroup Raises Price Target Significantly | BPMC Stock News - GuruFocus
Citi upgrades Blueprint Medicines stock rating after Sanofi acquisition - Investing.com
Blueprint Medicines (BPMC) Sees Upgrade and Acquisition by Sanofi | BPMC Stock News - GuruFocus
Blueprint Medicines Stock Surges as Sanofi Announces $9.5 Billion Acquisition - MSN
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines CorporationBPMC - Business Wire
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen - Insider Monkey
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform - Insider Monkey
Blueprint Medicines (BPMC) Downgraded Following Acquisition News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition News | BPMC Stock News - GuruFocus
Blueprint Medicines downgraded to Neutral from Buy at Guggenheim - TipRanks
Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC S - GuruFocus
Blueprint Medicines (BPMC) Downgraded by JMP Securities | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Wolfe Research | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Receives Downgrade from Stephens & Co. | BPMC Stock News - GuruFocus
Blueprint Medicines (BPMC) Downgraded Following Acquisition Deal | BPMC Stock News - GuruFocus
Sanofi to acquire US biotech firm Blueprint for up to $9.5bn - World Pharmaceutical Frontiers
Blueprint Medicines (BPMC) Downgraded Amid Sanofi Acquisition Pr - GuruFocus
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition - Investing.com
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition By Investing.com - Investing.com Nigeria
Citizens JMP downgrades Blueprint Medicines stock on Sanofi acquisition By Investing.com - Investing.com India
JPMorgan downgrades Blueprint Medicines stock after Sanofi acquisition By Investing.com - Investing.com Nigeria
TD Cowen cuts Blueprint Medicines stock rating following Sanofi acquisition - Investing.com
Blueprint Medicines downgraded to Neutral from Outperform at Wedbush - TipRanks
Blueprint Medicines stock hits all-time high of $128.04 By Investing.com - Investing.com South Africa
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday - Yahoo
Blueprint Medicines downgraded to Hold from Buy at Needham - TipRanks
Correction: French Drugmaker Sanofi to Buy US-based Blueprint Medicines for $9.5 Billion - marketscreener.com
JP Morgan Downgrades Blueprint Medicines (BIT:1BPMC) - Nasdaq
Blueprint Medicines Stock Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith - MSN
Sanofi to expand immunology offerings with Blueprint Medicines - Pharmaceutical Technology
Market Today: Sanofi Acquires Blueprint Medicines, BioNTech Part - GuruFocus
Blueprint Medicines downgraded to Hold from Buy at TD Cowen - TipRanks
Blueprint Medicines (BPMC) Downgraded After Acquisition Announce - GuruFocus
Weil Advises Sanofi in its $9.5 Billion Acquisition of Blueprint Medicines - Weil
Blueprint Medicines (BPMC) Downgraded After Sanofi's Acquisition Announcement | BPMC Stock News - GuruFocus
Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila - TipRanks
Market Today: Sanofi Acquires Blueprint Medicines, BioNTech Partners with Bristol Myers - GuruFocus
Sanofi to acquire Blueprint Medicines in US$9.5bn rare disease deal - Sharecafe
Cleveland-Cliffs, Tesla, GM, Blueprint Medicines, BioNTech, DraftKings, and More Movers - Barron's
Sanofi to Acquire Blueprint Medicines for $9.1 Billion - MSN
Sanofi to buy immunology biotech Blueprint for $9.1 billion - The Boston Globe
Citi maintains sell rating on Blueprint Medicines stock amid Sanofi deal By Investing.com - Investing.com South Africa
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Blueprint Medicines Corporation (BPMC) - TradingView
Sanofi to acquire Blueprint Medicines for $129 per share in cash - TipRanks
Sanofi acquires Blueprint Medicines for $129 per share or $9.1B - TipRanks
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):